Latest news with #AMWC
Forbes
3 days ago
- Business
- Forbes
Klotho Neurosciences: What's Behind The Nine-Fold Rise In KLTO Stock?
Monaco, Monte Carlo - March 28, 2024: 22nd Aesthetic and Anti-Aging Medicine World Congress AMWC at ... More the Grimaldi Forum. Face, Facial, Facelifting, Medicine, Beauty, Surgery, Mandoga Media Germany (Photo by Mandoga Media/picture alliance via Getty Images) Klotho Neurosciences (KLTO) witnessed an astonishing 800% increase in stock value on June 9, 2025, after revealing positive results from pre-clinical studies. The company's investigations indicated that enhancing Klotho gene expression may significantly lessen age-related deterioration across various organs while prolonging both lifespan and healthspan. Separately, see – What's Better – Circle Stock Or Bitcoin? The focus of Klotho's research is on the secreted protein s-KL, which has been identified as a potential anti-aging treatment owing to its wide-ranging biological impacts across various pathways linked to cellular damage, stress, and inflammation. In pre-clinical trials, the company employed an adeno-associated virus serotype 9 (AAV9) delivery vector to express the secreted KL protein isoform, successfully boosting serum s-KL levels and achieving a remarkable 20% increase in lifespan. [1] This method tackles aging as a key risk factor that contributes to numerous health issues, such as cognitive decline, neuroinflammation, sarcopenia, and osteoporosis. The company possesses exclusive patents in the USA, Europe, and China covering this secreted splice variant of mammalian Klotho for the treatment of neurodegenerative and age-related conditions. Even with the encouraging scientific basis, several key factors temper enthusiasm. The research is still in pre-clinical phases, which is the initial stage of drug development. The journey toward a commercially viable product necessitates extensive multi-year human trials, with no assurance of success. Historically, the vast majority of promising pre-clinical therapies do not succeed in becoming approved treatments. Financially, Klotho poses considerable risks. The company currently does not generate any revenue and has reported a negative net income of around $8 million over the past twelve months. KLTO's stock performance illustrates the severe volatility that is characteristic of penny stocks and early-stage biotechnology firms. The stock declined from a high of over $12 in March 2024 to below $0.20 last month before the recent dramatic rise to approximately $2. These significant price fluctuations highlight the speculative nature of investing in companies that have no current revenue and unproven technologies. While Klotho's anti-aging research embodies genuinely thrilling scientific potential, the investment comes with considerable risks. The combination of nascent science, absence of revenue, substantial cash burn, and extreme stock volatility makes KLTO a highly speculative investment, appropriate only for investors with a high-risk tolerance. Investors looking to gain exposure to pioneering healthcare advancements may want to consider diversified strategies, such as the Trefis High Quality (HQ) Portfolio, which distributes risk across multiple companies and sectors, rather than concentrating capital in individual speculative holdings. With a collection of 30 stocks, this portfolio has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a collective, HQ Portfolio stocks have yielded better returns with less risk compared to the benchmark index; offering a smoother investment experience, as evidenced in HQ Portfolio performance metrics.
Globe and Mail
09-04-2025
- Business
- Globe and Mail
BIOJUVE® Honoured as Best Cosmetics of the Year at AMWC 2025 in Monaco
Redefining Skin Biome Care with BIOJUVE NASHVILLE, Tenn. , /CNW/ -- Revance is proud to announce that BIOJUVE, the innovative skin biome care product from Crown Aesthetics, has been awarded the prestigious Best Cosmetics of the Year at the 12th Annual Aesthetic & Anti-Aging Medicine World Congress (AMWC), in Monaco , Montecarlo. The ceremony, which took place on March 27th at the Grimaldi Forum in Monaco , recognized excellence in aesthetics. BIOJUVE stood out among a competitive field of highly respected nominees. This accolade underscores BIOJUVE's commitment to advancing skin health through its unique approach to skin biome care. "We are incredibly honored that BIOJUVE has been recognized as the Best Cosmetics of the Year," said Jeff Bedard , Founder and CEO. "This award is a testament to our commitment to innovation and excellence in skin biome care. At Revance, we strive to develop cutting-edge solutions that redefine skincare, and BIOJUVE represents a breakthrough in harnessing the power of the skin's microbiome for healthier, more radiant skin. We are excited to continue leading the industry with science-backed, transformative products." The AMWC Awards celebrate physicians for excellence in clinical practice and recognize industry leaders for product and device development innovations within the aesthetics field. Winning this award highlights BIOJUVE and its significant impact on the industry and Revance's dedication to providing cutting-edge solutions for skin health. For more information about the age-defying power of a true skin probiotic with BIOJUVE, please visit About Revance Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life. With a differentiated portfolio of products spanning 60 countries, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and commercialization of new products and treatments.
Yahoo
08-04-2025
- Health
- Yahoo
Dr. Adam Scheiner Named "Best Surgical Facial Rejuvenation" at AMWC 2025 in Monaco
Only U.S. Surgeon Recognized by Global Panel for Breakthrough Laser Eyelid Rejuvenation Techniques TAMPA, Fla., April 08, 2025--(BUSINESS WIRE)--World-renowned laser eyelid and facial cosmetic surgeon Dr. Adam Scheiner was the only U.S. surgeon to receive an award at the 2025 Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco. Dr. Scheiner earned "Best Surgical Facial Rejuvenation" for his trailblazing methods of addressing complex under-eye concerns and rejuvenating the delicate eyelid area. Selected through AMWC's rigorous voting process, which included 77 international medical experts and peer attendees at this leading global aesthetic medicine event, Dr. Scheiner specializes in long-lasting, natural-looking results. His signature procedures—RESET® for Festoons and The Better Blepharoplasty™—effectively resolve conditions once deemed untreatable with traditional surgery. "I'm deeply honored to be recognized by such an esteemed panel—especially as the only U.S. surgeon awarded this year," said Dr. Scheiner. "This distinction underscores the importance of continuous innovation in laser cosmetic surgery for patients seeking safe, natural-looking rejuvenation around the eyes." Groundbreaking Laser Innovations Dr. Scheiner has spent over 25 years refining laser surgery and advanced resurfacing methods to reset patients' appearances by decades. RESET® for Festoons remains the only proven surgical treatment for festoons and malar bags, while The Better Blepharoplasty™ combines precise laser blepharoplasty with laser resurfacing to remove excess eyelid skin and restore a smooth, youthful look. For more information on Dr. Scheiner's Tampa-based practice and his eyelid and facial rejuvenation procedures, visit About Dr. Adam Scheiner Adam Scheiner, MD, is a Tampa-based, world-renowned laser eyelid and facial cosmetic surgeon, international speaker, expert trainer, and Wall Street Journal best-selling author of The True Definition of Beauty. Inventor of The Better Blepharoplasty™ and founder of RESET® for Festoons, he is redefining what's possible in eyelid and facial rejuvenation. His groundbreaking work has been featured on The Dr. Oz Show, The Doctors, The Howard Stern Show, The New York Post, and other major media outlets. Through advanced procedures, hands-on physician training, and an unwavering commitment to excellence, Dr. Scheiner continues to lead the field of laser cosmetic eyelid surgery—helping patients worldwide achieve a natural, rejuvenated appearance. About the Aesthetic & Anti-Aging Medicine World Congress (AMWC) The Aesthetic & Anti-Aging Medicine World Congress (AMWC) is a premier international conference dedicated to the latest advancements in aesthetic and anti-aging treatments, products, and services. Held annually, AMWC convenes top medical experts, researchers, and industry pioneers from around the globe to discuss emerging techniques and recognize breakthroughs in aesthetic medicine. View source version on Contacts Media Contact Elizabeth Kanna916-599-4039Elizabeth@ Sign in to access your portfolio
Mid East Info
03-04-2025
- Health
- Mid East Info
Dexlevo Successfully Concludes GOURI Symposium at AMWC 2025
Monaco, April, 2025 — Global biotech company Dexlevo successfully wrapped up a three-day Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2025 in Monaco, drawing significant international attention with its showcase of GOURI, the world's first liquid polycaprolactone (PCL) injectable. During the AMWC, Dexlevo held three symposiums from March 27 to 29, which brought together renowned medical professionals from around the world to explore the clinical innovations and efficacy of GOURI, a next-generation collagen biostimulator that is redefining the aesthetic medicine landscape. The first symposium opened with a keynote presentation by Dr. Akaluck Thammasunthorn from Thailand, titled 'The Possibilities of Liquid PCL GOURI: A Flexible and Powerful Anti-Aging Solution.' His in-depth lecture explored the unique advantages of liquid PCL in facial aesthetics and featured a live demonstration focusing on forehead application that received enthusiastic applause from attendees. One practitioner noted, 'The live demo clearly showed how easy GOURI's application is and how different it from any other conventional biostimulator. It was an inspiring way to open the first day of congress.' Dr. Olaf Young Fleischer from Germany continued the second-day clinical session with lecture on his clinical experiences and data-driven injection dosing strategies. Dr. Fleischer's session resonated strongly with attendees. A European dermatologist commented, 'His session offered valuable, practical insights I can apply in my clinic immediately.' Right after that Dr. Emmanouil Dimonitsas from Greece delivered a highly engaging presentation on the use of liquid PCL biostimulator GOURI in treating challenging areas and various dermatological conditions. In his lecture, Dr. Dimonitsas discussed the unique advantages of GOURI, emphasizing its role of the treatment in improving patients' quality of life. His presentation not only showcased advanced techniques but also reflected a deep understanding of aesthetic dermatology, earning him resounding applause and recognition from the audience. The last day symposium included Dr. Senhime Akashi's presentation from Japan which expanded the conversation beyond facial treatments with the topic of hand rejuvenation. Her talk explored the potential of liquid PCL for body-focused regenerative treatments, sparking wide interest among medical professionals seeking holistic anti-aging solutions. One attendee shared, 'Dr. Akashi's presentation opened new possibilities in body rejuvenation therapies using liquid PCL.' Dr. Mathelda Weni from Indonesia explored the role of liquid polycaprolactone as a product that enhances skin firmness and promotes natural lifting effects. She explained how liquid PCL works by stimulating collagen production over time, offering a non-surgical solution for patients seeking long-term skin rejuvenation. Throughout the conference, Dexlevo's exhibition booth became a dynamic hub for global networking, attracting medical professionals, academic leaders, and business partners from across the world. Visitors engaged with Dexlevo's medical research team, observed live demonstrations from the symposium, and gained insight into the company's international expansion strategy. As awareness grows globally around GOURI's safety, efficacy, and versatility, the product is gaining strong traction in overseas markets. With its foundation in the principles of Korean beauty, Dexlevo is quickly emerging as a leading brand in the global aesthetic medicine industry.
